In Brief: CBER Strategic Plan through 2004
CBER Strategic Plan through 2004: Will be discussed at FDA Vaccines & Related Biological Products Advisory Committee on Oct. 26. The committee will also hear presentations on Public Health Service-sponsored acellular pertussis trials. On Oct. 27, the committee will discuss whether a single formulation for pneumococcal conjugate vaccines should be used for children. The meeting will take place at the FDA Parklawn Building, conference rooms D & E, beginning at 8 a.m. both days...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth